FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer’s Disease in the US January 26, 2025
First Photorealistic AI Avatar for People Living with Alzheimer’s and Dementia Launched by Lenovo and Innovations in Dementia October 16, 2024
Fujirebio Submits FDA Regulatory Filing for Lumipulse® G pTau 217/ß-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease September 25, 2024
